Virtue sirolimus-eluting balloon granted breakthrough designation for coronary ISR

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

Virtue SEB, a drug/device combination product that delivers sustained-released bioabsorbable nanoparticle-encapsulated sirolimus directly to a patient’s artery during balloon angioplasty, works without the need for a drug coating, Orchestra said. It’s intended for use in individuals with coronary in-stent restenosis (ISR), a complication that comprises more than 10% of total interventional cardiology procedures.

Virtue delivers sirolimus, a common drug used to prevent ISR, to the artery with an elution profile that’s comparable to commercially available drug-eluting stents, according to Orchestra. To date, it’s the first and only non-coated sirolimus-eluting angioplasty balloon system to show promising clinical results in patients with coronary ISR, reaching 5.6% target lesion failure at three years in the SABRE trial.

The same study also found a 0% rate of major adverse cardiac events in-hospital and at one month post-implant and identified 0.12 mm late lumen loss at six-month angiographic assessment.

“In Virtue SEB, we finally have a therapeutic innovation that truly warrants breakthrough designation for the treatment of coronary ISR, a particularly challenging condition for which available treatment options are limited,” Dena Kereiakes, MD, medical director of the Christ Hospital Heart and Vascular Center and a professor of clinical medicine at Ohio State University, said in the release. “The unique design of Virtue SEB provides a reliable way to apply the proven anti-proliferative, anti-restenotic benefits of sirolimus during balloon angioplasty without the potential hazards of a permanent metal implant or a balloon coating that may produce downstream particulates and micro-emboli.”

The FDA grants devices breakthrough designation if there’s sufficient evidence that the technology could provide a more effective treatment for life-threatening or irreversibly debilitating diseases. The agency prioritizes the review of such devices, expediting their time to market.

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup